The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market. In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, includin...

The global idiopathic short stature market is expected to rise from USD 1.85 billion in 2026 to reach USD 5.08 billion by 2040, growing at a CAGR of 7.48% over the forecast period 2026 to 2040, driven by weekly growth hormone adoption, home-based treatment, and genetic reclassification of short stature. Based on Geography, North America captures 45.0% market share in 2026, whereas Asia-Pacific registers a 10.2% CAGR through 2040, driven by faster private endocrine care expansion. Based on Therap...

The global large volume wearable injectors market, valued at USD 12.6 billion in 2025, is projected to reach USD 16.4 billion in 2026 and USD 31.4 billion by 2035, representing a CAGR of 7.5% during the forecast period 2026 to 2035. The market numbers have been calculated by taking into account the revenues generated through sales of large volume wearable injectors and related drug-device combination products. Based on market share distribution by therapeutic area, devices used to treat autoimmu...

The global CRISPR based therapeutics market, valued at USD 0.1 billion in 2025, is projected to reach USD 0.2 billion in 2026 and USD 6.3 billion by 2035, with a CAGR of 43.8% during the forecast period 2026 to 2035. The CRISPR domain has evolved from basic scientific research into an important area of advanced therapeutics. Notably, the in vivo therapies segment is expected to grow at a significant pace during the forecast period due to rapid advancements in targeted gene-editing delivery techn...

The Europe non-viral transfection reagents market, valued at USD 0.22 billion in 2025, is projected to reach USD 0.24 billion in 2026 and USD 0.40 billion by 2035, representing a CAGR of 5.7% during the forecast period 2026-2035. Non-viral transfection reagents refer to chemical or physical delivery systems that introduce nucleic acids, including DNA, RNA, mRNA, siRNA, and gene editing components, into target cells without relying on viral vectors. In addition, rising investment in nucleic acid-...

The wearable injectors market, valued at USD 6.5 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 13.0 billion by 2035, representing a CAGR of 7.4% during the forecast period 2026 to 2035. Please note that the total wearable injectors market includes the sum of both insulin and non insulin drugs market. In terms of type of device, currently, the infusion pumps hold the highest share (more than 90%) of the insulin pumps market. The global surge in chronic disorders, such as...

The global cloud based drug discovery platforms market, valued at USD 3.7 billion in 2025, is projected to reach USD 4.2 billion in 2026 and USD 11.4 billion by 2035, representing a CAGR of 11.7% during the forecast period 2026 to 2035. Cloud based drug discovery platforms are centralized, internet-hosted software ecosystems that provide scalable computing power, data storage, and advanced analytics tools to accelerate the discovery of new therapeutic compounds. According to our projections, Nor...

The global RNAi technology market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.8 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 14.0% during the forecast period 2026 to 2035. RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses disease-causing genes at the messenger RNA (mRNA) level. Initially developed as a research tool, RNAi has evolved into a clinically validated therapeutic platform. Currently, the siRNA segment...

The global AI in clinical trials market, valued at USD 3.48 billion in 2025, is projected to reach USD 3.96 billion in 2026 and USD 11.61 billion by 2035, representing a CAGR of 12.7% during the forecast period 2026 to 2035. Based on the deployment mode, cloud-based AI solutions capture the largest share (around 75%) of the current market, and the trend is unlikely to change in the future. In terms of therapeutic areas, oncological disorders are expected to hold the largest market share (more th...

The global next generation contact lenses and visual prostheses market, valued at USD 0.36 billion in 2024, is projected to reach USD 0.60 billion in 2025 and USD 16.97 billion by 2035, representing a CAGR of 39.7% during the forecast period. It is worth highlighting here that there is a rapid increase witnessed in the number of blind and partially sighted individuals. According to the National Eye Institute, nearly 1.3 million people are blind, while 2.9 million individuals have poor vision, in...

The global cell therapy manufacturing market, valued at USD 6.3 billion in 2025, is projected to reach USD 7.2 billion in 2026 and USD 14.0 billion by 2035, representing a CAGR of 7.7% during the forecast period 2026 to 2035. Researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities across the globe. Further, several...

The global surgical robots market, valued at USD 9.8 billion in 2025, is projected to reach USD 10.6 billion in 2026 and USD 22.9 billion by 2035, with a 8.9% CAGR during the forecast period 2026 to 2035. In terms of geography, North America captures the majority of the market share.

The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a 8.1% CAGR during the forecast period 2026 to 2035. In terms of target antigen, the CD19 targeting therapies segment holds the highest share (more than 65%) of the market. With regards to target indication, the multiple myeloma segment dominates the global market with close to 30% market share. In terms of geographical regions, North America c...

The global mini bioreactors market, valued at USD 1.5 billion in 2025, is projected to reach USD 1.7 billion in 2026 and USD 4.0 billion by 2035, representing a CAGR of 10.4% during the forecast period 2026 to 2035. In terms of capacity of bioreactor, the 50 mL-250 mL segment holds the highest share of the current market. Based on the type of cell culture, the mammalian culture segment holds the largest share (close to 50%) of the current market.

The small scale bioreactors market is estimated to grow from USD 2,479 million in 2025 to reach USD 2,739 million in 2026 and USD 5,796 million by 2035, representing a CAGR of 8.68% during the forecast period 2026 to 2035. In 2025, the batch / fed batch mode of operation dominated the market and is estimated to hold 90% of the overall revenue share by 2035. Fed batch bioreactors provide controlled nutrient environment, preventing accumulation of inhibitory byproducts that can limit cell growth....

The global big data in healthcare market, valued at USD 93 billion in 2025, is projected to reach USD 110 billion in 2026 and USD 540 billion by 2035, with a 19.37% CAGR during the forecast period 2026 to 2035. The geographical regions segment highlights the distribution of big data in healthcare market across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world regions. According to our projections, the big data analytic...

The global contact lenses market, valued at USD 12.7 billion in 2025, is projected to reach USD 13.2 billion in 2026 and USD 20.5 billion by 2035, representing a CAGR of 5.0% during the forecast period 2026 to 2035. Contact lenses are thin, transparent optical devices placed directly on the cornea to correct refractive errors, and are currently worn by approximately 150 million individuals worldwide. In fact, in the US alone, an estimated 45 million people use contact lenses, with 87% opting fo...

The ultrasound market is estimated to grow from USD 9.6 billion in 2025 to reach USD 10.2 billion in 2026 and USD 16.0 billion by 2035, representing a CAGR of 5.1% during the forecast period. In May 2026, ClearPoint Neuro entered into a collaboration with Sungkyunkwan University to expand its drug delivery ecosystem. The collaboration follows successful preclinical trials demonstrating ultrasound-enabled delivery across the blood-brain barrier, aiming to accelerate commercialization and global e...

The global Fc fusion protein market, valued at USD 40.7 billion in 2025, is projected to reach USD 45.0 billion in 2026 and USD 103.7 billion by 2035, representing a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of type of fusion molecule, receptor ECD segment holds the highest share of the current market. In March 2026, Shanghai Henlius Biotech dosed the first patient in a Phase 1b/2 trial of HLX701, a next-generation SIRPα-Fc fusion protein, in combination with cetuximab and...

The global nanoparticle formulation market, valued at USD 6.2 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 15.2 billion by 2035, with a CAGR of 9.3% during the forecast period 2026 to 2035. In June 2026, CEPI announced up to $9.7 million in additional funding to POP Biotechnologies to advance its SNAP nanoparticle-based vaccine platform into Phase 1 trials. The program targets rapid-response vaccines for epidemic threats such as H5N1 and Disease X, aiming to improve ant...